Drug Shortage Report for HALOPERIDOL INJECTION, USP
| Report ID | 50916 |
| Drug Identification Number | 02406411 |
| Brand name | HALOPERIDOL INJECTION, USP |
| Common or Proper name | HALOPERIDOL |
| Company Name | FRESENIUS KABI CANADA LTD |
| Market Status | MARKETED |
| Active Ingredient(s) | HALOPERIDOL |
| Strength(s) | 5MG |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAMUSCULAR |
| Packaging size | 1mL MD Vial |
| ATC code | N05AD |
| ATC description | ANTIPSYCHOTICS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | 2018-05-28 |
| Actual start date | |
| Estimated end date | |
| Actual end date | 2018-08-02 |
| Shortage status | Resolved |
| Updated date | 2018-08-10 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v5 | 2018-08-10 | French | Compare |
| v4 | 2018-08-10 | English | Compare |
| v3 | 2018-05-30 | French | Compare |
| v2 | 2018-05-30 | English | Compare |
| v1 | 2018-05-30 | English | Compare |
Showing 1 to 5 of 5